An observational study in Dual Diagnosis, Substance Use Disorder and Mental Disorders, sponsored by Hospital Virgen del Puerto. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Hospital Virgen del Puerto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Substance-Related Disorders with a site in Spain — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Spain.
Among the 26 studies in Substance-Related Disorders with a site in Spain, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 26th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 26 studies in Substance-Related Disorders with a site in Spain are open now. Recruiting first, the newest first:
Clínica Nuestra Señora de la Paz · Sites in Spain
Ages 18–90
NORCE Norwegian Research Centre AS · Sites in Spain, Austria, Israel and 5 more countries
Ages 18+
University of Huelva · Sites in Spain
Ages 18+
University of Santiago de Compostela · Sites in Spain
Ages 40+ · Healthy volunteers
University of Valencia · Sites in Spain
Ages 18+ · Men only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 125 is below the median of 250 across 299 observational studies indexed under Substance-Related Disorders.
Median enrollment 131 across the 20 interventional studies, 403 across the 6 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hospital Virgen del Puerto as lead sponsor.
Hospital Virgen del Puerto has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Substance-Related Disorders with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052175Clínica Nuestra Señora de la PazPrevention of Relapse in Behavioral Disorders | 2026-12 |
| NCT07443033Hospital Virgen del PuertoPsychosocial Factors in Dual Diagnosis in a General Hospital | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Substance-Related Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dual diagnosis, defined as the co-occurrence of a mental disorder and a substance use disorder, is frequently associated with increased clinical severity, functional impairment, and poorer health outcomes. Identifying psychosocial protective factors related to better clinical and functional outcomes is essential to improve patient care and treatment planning.
The aim of this observational, cross-sectional, single-center study is to analyze psychosocial protective factors and their association with clinical-functional outcomes in hospitalized patients with dual diagnosis. The study will be conducted in a general hospital setting and will include adult inpatients diagnosed with dual diagnosis according to clinical criteria.
Sociodemographic, clinical, and psychosocial variables will be collected using standardized assessment tools and clinical records. The results of this study are expected to contribute to a better understanding of psychosocial factors associated with clinical severity and functional outcomes in patients with dual diagnosis, supporting more comprehensive and patient-centered care approaches.
Dual diagnosis, characterized by the coexistence of a mental disorder and a substance use disorder, represents a major clinical challenge in mental health services. Patients with dual diagnosis frequently present greater clinical complexity, higher rates of hospitalization, functional impairment, and difficulties in treatment adherence. Beyond clinical variables, psychosocial factors may play a relevant role as protective elements influencing clinical and functional outcomes.
This study is designed as an observational, cross-sectional, single-center study conducted in a general hospital. The study population will consist of adult patients hospitalized with a clinical diagnosis of dual diagnosis. Participants will be recruited during their hospital admission according to predefined inclusion and exclusion criteria.
Data collection will include sociodemographic information, clinical variables related to psychiatric and substance use disorders, and psychosocial factors considered potentially protective. Clinical-functional outcomes will be assessed using standardized instruments and information obtained from medical records. All data will be collected as part of routine clinical assessment, without introducing any experimental intervention.
The primary objective of the study is to evaluate the association between psychosocial protective factors and clinical-functional outcomes in hospitalized patients with dual diagnosis. Secondary objectives include describing the sociodemographic and clinical characteristics of the study population and exploring the relationship between psychosocial variables and indicators of clinical severity.
This study does not involve the administration of investigational drugs or devices and does not modify standard clinical practice. The research protocol has been reviewed and approved by the corresponding Ethics Committee. The findings are expected to provide relevant information to support a biopsychosocial approach in the assessment and management of patients with dual diagnosis.
Adult inpatients hospitalized in a general hospital with a clinical diagnosis of dual diagnosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult inpatients diagnosed with dual diagnosis hospitalized in a general hospital.
Medication adherence measured by Simplified Medication Adherence Questionnaire (SMAQ)
Medication adherence assessed using the 6-item Simplified Medication Adherence Questionnaire (SMAQ). Participants will be classified as adherent or non-adherent according to the original scoring criteria.
Time frame: Baseline (within 72 hours of hospital admission)
Observed treatment adherence during hospitalization (clinical proxy index 0-3)
Treatment adherence during hospital stay assessed using a structured clinical proxy index derived from medical records. The index ranges from 0 to 3 (0 = ≤33% adherence; 1 = 34-66%; 2 = 67-89%; 3 = ≥90%), based on medication compliance and participation in therapeutic activities.
Time frame: At hospital discharge (average length of stay approximately 10-14 days)
Clinical severity measured by Clinical Global Impression - Severity scale (CGI-S)
Global clinical severity assessed by the treating psychiatrist using the 7-point Clinical Global Impression - Severity scale (1 = normal, 7 = extremely ill). Higher scores indicate greater illness severity.
Time frame: Baseline (within 72 hours of hospital admission)
Health-related quality of life measured by EuroQol-5D-5L index score
Health-related quality of life assessed using the EQ-5D-5L descriptive system. The utility index score (range depends on national value set; typically \<0 to 1, where 1 indicates full health) will be calculated according to the Spanish value set.
Time frame: Baseline (within 72 hours of hospital admission)
Self-rated health status measured by EQ-5D Visual Analog Scale (VAS)
Self-reported health status measured on a 0-100 visual analog scale, where 0 represents the worst imaginable health state and 100 the best imaginable health state.
Time frame: Baseline (within 72 hours of hospital admission)
Suicidal ideation measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Presence of suicidal ideation assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). Participants will be categorized as having any suicidal ideation (yes/no) during the assessment.
Time frame: Baseline (within 72 hours of hospital admission)
Plan to share: No — Individual participant data will not be shared to protect participant confidentiality and in accordance with local ethics committee approval and institutional data protection regulations.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.